Metabolomic profiles and pathogenesis of nephrolithiasis.
Journal
Current opinion in nephrology and hypertension
ISSN: 1473-6543
Titre abrégé: Curr Opin Nephrol Hypertens
Pays: England
ID NLM: 9303753
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
pmc-release:
01
09
2024
medline:
3
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
Kidney stone disease is caused by supersaturation of urine with certain metabolites and minerals. The urine composition of stone formers has been measured to prevent stone recurrence, specifically calcium, uric acid, oxalate, ammonia, citrate. However, these minerals and metabolites have proven to be unreliable in predicting stone recurrence. Metabolomics using high throughput technologies in well defined patient cohorts can identify metabolites that may provide insight into the pathogenesis of stones as well as offer possibilities in therapeutics. Techniques including 1H-NMR, and liquid chromatography paired with tandem mass spectroscopy have identified multiple possible metabolites involved in stone formation. Compared to formers of calcium oxalate stones, healthy controls had higher levels of hippuric acid as well as metabolites involved in caffeine metabolism. Both the gut and urine microbiome may contribute to the altered metabolome of stone formers. Although metabolomics has offered several potential metabolites that may be protective against or promote stone formation, the mechanisms behind these metabolomic profiles and their clinical significance requires further investigation.
Identifiants
pubmed: 37530089
doi: 10.1097/MNH.0000000000000903
pii: 00041552-202309000-00015
pmc: PMC10403267
mid: NIHMS1902240
doi:
Substances chimiques
Calcium Oxalate
2612HC57YE
Calcium
SY7Q814VUP
Oxalates
0
Types de publication
Review
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
490-495Subventions
Organisme : NIDDK NIH HHS
ID : P01 DK056788
Pays : United States
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
J Urol. 2022 Apr;207(4):851-856
pubmed: 34854755
J Urol. 2014 Nov;192(5):1440-5
pubmed: 24929140
Front Cell Infect Microbiol. 2022 Sep 05;12:953392
pubmed: 36132987
J Am Soc Nephrol. 2010 Oct;21(10):1641-4
pubmed: 20616170
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 15;1124:290-297
pubmed: 31255901
BMJ. 2012 Aug 29;345:e5287
pubmed: 22936784
Neurol Sci. 2021 Nov;42(11):4521-4529
pubmed: 33606128
Am J Kidney Dis. 2013 Jun;61(6):923-9
pubmed: 23433467
Healthcare (Basel). 2023 Feb 02;11(3):
pubmed: 36766999
Kidney Int. 2004 Feb;65(2):386-92
pubmed: 14717908
Urolithiasis. 2015 Jan;43 Suppl 1:19-32
pubmed: 25108546
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):411-420
pubmed: 30745301
Int J Epidemiol. 2022 Jan 6;50(6):1995-2010
pubmed: 34999880
J Clin Invest. 2005 Oct;115(10):2598-608
pubmed: 16200192
JAMA. 2013 Jul 24;310(4):408-15
pubmed: 23917291
J Am Soc Nephrol. 2022 Nov;33(11):2071-2086
pubmed: 36316097
J Urol. 2014 Aug;192(2):316-24
pubmed: 24857648
Clin Transl Sci. 2021 Jul;14(4):1327-1337
pubmed: 33580996
Curr Opin Urol. 2023 Mar 1;33(2):129-135
pubmed: 36562282
Nutrition. 2019 Mar;59:83-89
pubmed: 30471528
Urolithiasis. 2020 Feb;48(1):27-35
pubmed: 30949730
Sci Rep. 2019 Apr 1;9(1):5425
pubmed: 30932002
J Urol. 2017 Jun;197(6):1465-1471
pubmed: 28111301
J Am Soc Nephrol. 2020 Jun;31(6):1358-1369
pubmed: 32381601
Urology. 2022 Sep;167:49-55
pubmed: 35716870
Kidney360. 2021 Nov 30;3(2):317-324
pubmed: 35373120
J Am Soc Nephrol. 2017 Jan;28(1):333-347
pubmed: 27297950
J Urol. 2018 May;199(5):1262-1266
pubmed: 29132983
Clin J Am Soc Nephrol. 2020 Mar 6;15(3):404-411
pubmed: 31636087
BMC Fam Pract. 2010 Jun 21;11:49
pubmed: 20565929
Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2141-6
pubmed: 25278549
Ann Intern Med. 2013 Apr 2;158(7):535-43
pubmed: 23546565
Am J Kidney Dis. 2022 Jan;79(1):3-4
pubmed: 34690003